If your trading or investing in penny stocks which are not OTC stocks, then these three pharmaceutical companies have Nasdaq listed shares that you should add to your list of penny stocks to watch immediately: Alexza Pharmaceuticals (ALXA), Zalicus Inc. (ZLCS) and Sunesis Pharmaceuticals (SNSS).
Shares in Alexza Pharmaceuticals (Nasdaq: ALXA) are down -23.98% YTD, more than -95% since the penny stock peaked 5 years ago. ALXA closed up 1.77% at $0.631 on volume of 5.4 million in the last trading session. The company has a pending May 4th PDUFA date for AZ-004 (Staccato Loxapine) for agitation in schizophrenic or bipolar patients.
Looking for Cheap Stocks? Subscribe and get our next penny stock picks FREE.
Shares in the penny stock of Zalicus Inc (Nasdaq: ZLCS) closed down nearly -2% in the last trading session at $1.03 on volume of 1.636 million. ZLCS was down -8.85% last week and -14.88% YTD. Most of the focus on ZLCS has been directed at its pain-management therapy, Exalgo.
The penny stock price of Sunesis Pharmaceuticals (Nasdaq: SNSS) appreciated 6.64% last week after having a big trading session closing up 10.11% at $3.05. SNSS shares are up 160.68% YTD and could go even higher considering the biotech has Phase 3 interim analysis of its drug, Vosaroxin, in patients with first relapsed or refractory acute myeloid leukemia (AML) due out in Q3, 2012.
ALXA Stock Snap Shot:
Market Cap: 73.28M
(Jun 30, 2011): 1.91
(Feb 17, 2012): 0.4612
Avg Vol (3 month): 1,009,180
Avg Vol (10 day): 2,054,970
Shares Outstanding: 116.14M
% Held by Insiders: 30.16%
If ALXA‘s Adasuve treatment is approved on May 4, shares could skyrocket well above $1. Alexza has been suffering from a severe cash crisis even after recent stock dilutions.
To view the SEC filings for ALXA, click here.
ZLCS Stock Snap Shot:
Market Cap (intraday): 101.63M
(Apr 28, 2011): 3.21
(Oct 4, 2011): 0.82
Avg Vol (3 month): 1,550,390
Avg Vol (10 day): 1,408,310
Shares Outstanding: 98.67M
% Held by Insiders: 13.26%
Exalgo may be the only product ZLCS has on the market, but investors would be wise to look at the bigger picture with the biotech. ZLCS has an advanced pipeline candidate, Synavive, which is used to treat immuno-inflammatory disorders. The clinical trials for the drug have moved ahead successfully with results of phase 2b trials due later this year. A positive outcome at this stage could send a rush of buying into the penny stock of Zalicus.
To view the SEC filings for ZLCS, click here.
SNSS Stock Snap Shot:
Market Cap: 142.80M
(Apr 13, 2012): 3.19
(Oct 4, 2011): 1.01
Avg Vol (3 month): 424,408
Avg Vol (10 day): 605,943
Shares Outstanding: 46.82M
% Held by Insiders: 37.20%
Wall Street analyst firm Cantor Fitzgerald initiated a “buy” rating on SNSS last week. Sunesis is not a profitable company and is not expected to become one anytime inthe near future. SNSS currently trades at 26X its annual revenue stream, 2X sales ratios which only big-pharma giants like AstraZeneca or Pfizer trade at.
To view the SEC filings for SNSS, click here.
Bottom Line: Our penny stock picks this week; ALXA, ZLCS and SNSS all should be added to your list of penny stocks to watch and approached with the intent to play press release bingo on them. Penny stock speculators trading biotechs can hope to discover the next Viagra if they want but even if Wall Street analysts are right, short-term trades and day-trades on PDUFA dates are best set for these stocks.
Good news or comments from any high level positioned persons in any of these companies can positively move these penny stocks significantly.
ALXA PDUFA date May 4 for AZ-004 (Staccato Loxapine) for agitation in schizophrenic or bipolar patients.
hi�K il�~1@s metal projects throughout North America. Focusing on high yield gold and silver projects, Vatic Ventures currently holds two projects, the BM gold property in the Spences Bridge Gold Belt near Merritt, BC and has a Lease/Option-to-Purchase Agreement for the La Silla West property near Mazatlan. The company continues to explore new opportunities and prospects. We will be performing further due diligence on the Company in the coming weeks, but given the sudden awakening of the stock price and volume, we wanted to alert our investors to this Company as soon as possible and encourage them to follow developments in Vatic Ventures into next week to see if the volume and price spike can continue.